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The cannabinoid type two receptors (CB2), an important component of the
endocannabinoid system, have recently emerged as neuromodulators and therapeutic
targets for neurodegenerative diseases including Parkinson’s disease (PD). The
downregulation of CB2 receptors has been reported in the brains of PD patients.
Therefore, both the activation and the upregulation of the CB2 receptors are believed
to protect against the neurodegenerative changes in PD. In the present study, we
investigated the CB2 receptor-mediated neuroprotective effect of β-caryophyllene
(BCP), a naturally occurring CB2 receptor agonist, in, a clinically relevant, rotenone
(ROT)-induced animal model of PD. ROT (2.5 mg/kg BW) was injected intraperitoneally
(i.p.) once daily for 4 weeks to induce PD in male Wistar rats. ROT injections
induced a significant loss of dopaminergic (DA) neurons in the substantia nigra pars
compacta (SNpc) and DA striatal fibers, following activation of glial cells (astrocytes
and microglia). ROT also caused oxidative injury evidenced by the loss of antioxidant
enzymes and increased nitrite levels, and induction of proinflammatory cytokines:
IL-1β, IL-6 and TNF-α, as well as inflammatory mediators: NF-κB, COX-2, and iNOS.
However, treatment with BCP attenuated induction of proinflammatory cytokines and
inflammatory mediators in ROT-challenged rats. BCP supplementation also prevented
depletion of glutathione concomitant to reduced lipid peroxidation and augmentation of
antioxidant enzymes: SOD and catalase. The results were further supported by tyrosine
hydroxylase immunohistochemistry, which illustrated the rescue of the DA neurons and
fibers subsequent to reduced activation of glial cells. Interestingly, BCP supplementation
demonstrated the potent therapeutic effects against ROT-induced neurodegeneration,
which was evidenced by BCP-mediated CB2 receptor activation and the fact that, prior
administration of the CB2 receptor antagonist AM630 diminished the beneficial effects of
BCP. The present study suggests that BCP has the potential therapeutic efficacy to elicit
significant neuroprotection by its anti-inflammatory and antioxidant activities mediated
by activation of the CB2 receptors.
Keywords: AM630, β-caryophyllene, cannabinoid agonist, neurodegeneration, neuroprotection, Parkinson’s
disease, rotenone, Trans-caryophyllene
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INTRODUCTION
The endocannabinoid system, consisting of cannabinoid
receptors type 1 and 2 (CB1 and CB2), their endogenous
ligands, and the enzymes for synthesis, reuptake and metabolism
of the endocannabinoids, has emerged as an important
neuromodulator system for many brain functions such as
learning, memory, mood, addiction, and reward processing
(Hill et al., 2009; Zanettini et al., 2011). Among the cannabinoid
receptors, the CB2 receptor subtype has recently gained attention
as an important therapeutic target for the modulation of
neuroinflammation and attenuation of activated microglia and
astrocytes in the substantia nigra and striatum (Bento et al.,
2008; Concannon et al., 2015). The pharmacological activation
of the CB2 receptors has been shown to reduce microglial
activation and improve functional deficits in neurodegenerative
diseases including Alzheimer’s disease (Ramírez et al., 2005),
Huntington’s disease (Palazuelos et al., 2009; Sagredo et al.,
2009), multiple sclerosis (Palazuelos et al., 2008), and PD
(Price et al., 2009). In addition to the pharmacological studies,
genetic studies also demonstrate enhanced microglial activation,
neural pathology and inflammation in CB2 receptor knock-out
mice (Palazuelos et al., 2008; Price et al., 2009). These studies
indicated that cannabinoid-related compounds activating CB2
receptors may preserve neuronal homeostasis and survival in
neurodegenerative disorders, including PD (Fernandez-Ruiz
et al., 2007).
Furthermore, the CB2 receptor activation has been
shown to be devoid of psychotropic, adverse effects, which
are frequently observed with CB1 receptor modulation.
Among the cannabinoid ligands, β-caryophyllene (BCP)
generated enormous therapeutic interest due to its noteworthy
identification as a fully selective agonist of CB2 receptors, its
affinity and binding with CB2, receptors along with favorable
physicochemical and pharmacokinetic properties (Figure 1;
Gertsch et al., 2008). It is one of the widely available dietary
phytocannabinoids and is commonly used as a preservative,
additive, and flavoring in food and cosmetics. It has been recently
added to the list of “generally regarded as safe” compounds for
dietary use by the United States Food and Drug Administration
(Gertsch et al., 2008). Chemically, BCP is a bicyclic sesquiterpene
abundantly found in the essential oils of different species such as
Cinnamomum spp. and Piper spp (Passos et al., 2004; Medeiros
et al., 2007). BCP is a secondary metabolite predominantly found
in many dietary plants that exhibits potent and long-lasting
antioxidant and anti-inflammatory properties in different
models of human diseases (Sharma et al., 2016). BCP is also
an important constituent of Cannabis sativa that makes one
of the major ingredients of Sativex, an approved drug for
multiple sclerosis in European countries and Canada (Sibbald,
2005). BCP has been shown to elicit potent pharmacological
properties such as anti-inflammatory (Gertsch et al., 2008),
antioxidant (Singh et al., 2006), antispasmodic (Leonhardt
et al., 2010), antidepressant and anxiolytic (Galdino et al.,
2012; Al Mansouri et al., 2014), and anti-addictive (Bahi et al.,
2014). Pharmacologically, it has been reported to be a CB2
receptor-selective agonist with a Ki value of 155 nmol/L for
FIGURE 1 | Chemical structure of β-caryophyllene (A) and AM630 (B).
human CB2 receptors, with no affinity for CB1 receptors, which
causes activation of Gi/Go subtype of G-proteins (Gertsch et al.,
2008). The identification and participation of CB2 receptors in
mediating neuroprotection has driven special interest in the
pharmacological investigation of BCP for neurodegenerative
disorders including PD.
Among the neurodegenerative diseases, PD is the second
most common progressive disease. It is characterized by the
selective degeneration of dopaminergic neurons in the substantia
nigra pars compacta (SNpc) and depletion of dopamine
neurotransmitter in the striatum (Shimohama et al., 2003).
The pathogenesis of PD involves enhanced oxidative stress and
mitochondrial dysfunction caused by the selective inhibition
of the activity of complex I of the mitochondrial respiratory
chain (Hu et al., 2010). The available evidence has shown
that the decreased activity of the mitochondrial complex I has
been observed in the SNpc of PD patients (Schapira, 1989)
accompanied by increased oxidative/nitrosative stress (Jenner,
2003). The reactive oxygen species (ROS) generated from
unregulated dopamine metabolism and auto-oxidation (Cadet
and Brannock, 1998) further impair mitochondrial function
(Tapias et al., 2009) and alter defensive endogenous antioxidant
systems together leading to oxidative stress and contributing
to progressive loss of dopaminergic neurons. Numerous studies
have demonstrated that increased production of cytokines and
ROS as well as induction of NADPH oxidase and inducible
nitric oxide synthase (iNOS) leads to glial cells activation
that contributes to PD pathology (Chen and Tansey, 2011).
Therefore, interplay between the oxidative stress and subsequent
neuroinflammation perpetuates neurodegeneration in PD (Lee
et al., 2009).
Rotenone (ROT) induced rat model of PD was employed
in the present study to investigate the therapeutic effects of
BCP. ROT is a rotenoid pesticide used for understanding the
pathogenesis of PD and evaluation of pharmacotherapeutic
agents. It causes selective nigrostriatal degeneration,
accumulation and aggregation of α-synuclein, oxidative
stress, inflammation, microglial activation, abnormal locomotor
activity, impaired motor functions, and disrupts mitochondrial
complex I activity resulting in pathology strikingly similar
to that observed in human PD patients (Betarbet et al.,
2006; Cannon et al., 2009; Thakur and Nehru, 2013; Tapias
et al., 2014). In the present study, we have investigated the
Frontiers in Neuroscience | www.frontiersin.org 2 August 2016 | Volume 10 | Article 321
Javed et al. CB2 Receptors Activation Protects Parkinson’s Disease
neuroprotective effects of BCP in ROT induced rat model
of PD, via CB2 receptor-dependent mechanism by using a
selective CB2 receptor antagonist AM630 (Figure 1). AM630
(iodopravadoline) is a novel aminoalkylindole and a competitive
cannabinoid receptor antagonist in the brain that is commonly
employed as a pharmacological challenge to demonstrate
the CB2 receptor dependent mechanisms (Hosohata et al.,
1997). BCP has potential anti-inflammatory and anti-oxidant
activity and is widely accessible for dietary intervention.
We believe that our present findings may have important
pharmacotherapeutic significance in the treatment/prevention
of PD.
MATERIALS AND METHODS
Drugs and Chemicals
Polyclonal rabbit anti-cyclo-oxygenase-2 (COX-2), anti-
inducible nitric oxide synthase (iNOS), anti-glial fibrillary
acidic protein (GFAP), anti-cannabinoid receptor type 2 (CB2)
and anti-NF-kB p65 antibodies were purchased from Abcam,
Cambridge, MA, USA. Anti-ionized calcium binding adaptor
molecule-1 (Iba-1) polyclonal rabbit antibody was purchased
from Wako Chemicals, Richmond, VA, USA. Polyclonal rabbit
anti-tyrosine hydroxylase (TH) antibody was obtained from
Novus Biologicals, Littleton, CO, USA. Alexa Fluor R© 488 and 594
conjugated secondary goat anti-rabbit antibodies were purchased
from Life Technologies, Grand Island, NY, USA. CB2 receptor
antagonist, AM630 ([6-Iodo-2-methyl-1-[2-(4-morpholinyl)
ethyl]-1H-indol-3-yl] (4-methoxyphenyl) methanone) was
purchased from Tocris Bioscience, Ellisville, MO, USA. The
lipid peroxidation kit for estimation of malondialdehyde
(MDA) was obtained from North West Life science (Vancouver,
WA, USA). The compounds: ROT, BCP and the assay kit
for GSH were procured from Sigma-Aldrich, St. Louis, MO,
USA. All the reagents used in the study were of analytical
grade.
Experimental Animals
Six to seven months-old male Wistar rats (275–300 g), bred
in the animal research facility of the College of Medicine and
Health Sciences, United Arab Emirates University, were used.
A maximum of four rats were housed per cage and were
acclimatized for 1 week to the laboratory conditions prior to
the start of the experiment. The animals were housed under
standard laboratory conditions of 12/12 h of light and dark
cycle. The animals had access to commercially available rodent
food and water ad libitum. All the experiments were performed
between 09:00 and 15:00 h. The experimental protocol for animal
experimentation was approved by the Animal Ethics Committee
of United Arab Emirates University, UAE.
Experimental Design
For the induction of PD in rats, ROT (2.5 mg/kg BW) was
administered intraperitoneally (i.p.) once daily for 4 weeks.
ROT was first dissolved in dimethyl sulfoxide (DMSO) at 50X
stock solution and further diluted in sunflower oil to obtain
a final concentration of 2.5 mg/ml. The regimen used in the
current study for the induction of Parkinsonism in rats by
ROT administration was described in a previous report (Ojha
et al., 2015). To test the neuroprotective efficacy of CB2 receptor
agonist, BCP, it was diluted in olive oil and administered i.p. at
a dose of 50 mg/kg BW once daily for 4 weeks, 30 min prior
to ROT administration in the presence or absence of AM630,
a CB2 receptor antagonist. The dose of BCP was selected based
on our previous study, in which a different set of experiments
showed this dose to be pharmacologically optimal and devoid
of any in vivo toxicity (Al Mansouri et al., 2014). The control
group received a similar volume of vehicle. AM630 was dissolved
in normal saline with 2.5% DMSO and tween 80 and injected 1
mg/kg BW i.p. 30 min prior to BCP treatment. The rats were
divided into five groups as follows: Group I: Rats were injected
vehicle only and abbreviated as control group (CONT), Group II:
Rats were injected AM630 only and abbreviated as group AM630,
Group III: Rats were injected rotenone dissolved in the vehicle
and abbreviated as group ROT, Group IV: Rats were administered
BCP, 30 min prior to rotenone injections and abbreviated as
group ROT+BCP, Group V: Rats were administered AM630, 30
min prior to BCP treatment and rotenone and abbreviated as
(ROT-BCP+AM630).
Tissue Preparation for Biochemical Studies
At the end of the 4 weeks, the animals were anesthetized
with pentobarbital (40 mg/kg BW) and cardiac perfusion was
performed using phosphate-buffered saline (PBS, 0.01 M, pH
7.4) to wash out the blood. The brains were quickly removed
and placed on an ice plate to separate the two hemispheres.
The midbrain and striatum were dissected from one hemisphere
and immediately frozen in liquid nitrogen for further use.
The other hemisphere was post-fixed first in paraformaldehyde
solution (4%) for 48 h and subsequently in a series of sucrose
solutions (10%) at 4◦C changed three times a day for up to three
consecutive days prior to cryostat sectioning.
Biochemical Studies
The midbrains of the rats collected from each group were
homogenized in potassium chloride buffer at pH 8.0 (Tris-
HCl 10 mM, NaCl 140 mM, KCl 300 mM, EDTA 1 mM,
Triton X-100 0.5%) and supplemented with protease and
phosphatase inhibitor. The tissue homogenates of the samples
were centrifuged at 14000 g for 20 min at 4◦C to obtain the post-
mitochondrial supernatant (PMS) for estimation of antioxidant
enzymes, lipid peroxidation product, and proinflammatory
cytokines using spectrophotometric measurements and enzyme-
linked immunosorbent assay (ELISA).
Estimation of Lipid Peroxidation Product
The extent of lipid peroxidation was measured by estimation
of malondialdehyde (MDA). Briefly, the samples or calibrators
(250 µl) were incubated in the presence of acid reagent and
thiobarbituric acid (250 µl) and mixed vigorously using a vortex
mixer. The samples were incubated for 60 min at 60◦C and
then centrifuged at 10,000 g for 2–3 min. The resultant reaction
mixture was transferred to a cuvette and the absorbance was
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FIGURE 2 | The expression level of cannabinoid receptor 2 (CB2)
measured by western blot in the striatum. (A) The western blot showing
CB2 expression. (B) CB2 expression was decreased in the ROT group as
compared to the CONT group rats. However, BCP supplementation of ROT
injected rats showed increased expression of CB2 receptors. Selective
antagonist of CB2 receptors, AM630 administration prior to BCP
supplementation decreased the expression of CB2 receptors. AM630
administration to ROT injected rats has not shown any noticeable difference in
the expression of CB2. Finally, AM630 alone had no effect on the level of CB2
expression as compared to control rats. Values are expressed as percent (%)
mean ± SEM (n = 3).
recorded at 532 nm. The results were expressed as µMMDA/mg
protein.
Estimation of GSH
The amount of GSH was estimated following the manufacturer’s
instructions for the commercially available kit. Briefly, the
samples were first de-proteinized with 5-sulfosalicylic acid
solution (5%) and centrifuged to remove the precipitated protein.
The supernatant was used to estimate the amount of GSH.
The samples or standards (10 µl) were incubated with 150
µl of working mixture (assay buffer with 5,5′-Dithiobis (2-
nitrobenzoic acid) and glutathione reductase) in a 96-well plate
for 5 min. Diluted NADPH solution (50 µl) was added to each
well and mixed thoroughly. The absorbance of the samples was
recorded at 412 nm using the microplate reader after 5min
incubation period. The results were expressed as µM GSH/mg
protein.
Antioxidant Enzymes Activity
The activities of antioxidant enzymes: superoxide dismutase
(SOD) and catalase (CAT) were estimated using assay kits
(Cayman Chemicals Co., Ann Arbor, MI, USA). Briefly, the
activity of SOD was estimated by adding samples or standards
(10 µl) to a 96-well plate. Xanthine oxidase (20 µl) was added
to each well to initiate the reaction and the plate was shaken
for a few seconds, afterwards it was covered and incubated for
30 min at room temperature. The absorbance was recorded
using the microplate reader at 450 nm. The activity of CAT was
estimated by adding samples or standards (20 µl) to the assay
buffer (100µl) andmethanol (30µl) in a 96-well plate. Hydrogen
peroxide solution (20 µl) was added to initiate the reaction and
incubated for 20 min at room temperature. Potassium hydroxide
(30µl) was added to terminate the reaction, subsequently catalase
purpald (30 µl) and catalase potassium periodate (10 µl) were
added. The plate was incubated for 5 min at room temperature
on a shaker and absorbance was read at 540 nm using the
microplate reader. The SOD activity was expressed as U/mg
protein and the CAT activity was expressed as nmol·min−1·mg−1
protein.
Estimation of Nitrite Levels
The nitrite levels were estimated using a commercially available
kit (R&D system, Minneapolis, MN, USA). Briefly, the sample or
nitrite standard (50 µl) was added with reaction diluent (50 µl)
to a 96-well plate supplied by the manufacturer. Subsequently,
Griess reagent (50µl) was added to each well andmixed by gentle
tapping on the side of the plate. The plate was incubated for
10 min at room temperature and the absorbance was measured
at 540 nm using the microplate reader. The nitrite levels were
expressed as µmol/mg protein.
Estimation of Proinflammatory Cytokines
The levels of proinflammatory cytokines: interleukin-1β (IL-
1β), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-
α) were estimated using the commercially available ELISA
kits purchased from R&D system (Minneapolis, MN, USA).
Briefly, a 96-well plate was coated with the diluted capture
antibody (100 µl) overnight at room temperature. Each well
was aspirated and washed with the wash buffer (0.05% tween
20 in PBS 0.01M pH7.4). The plate was blocked by adding
reagent diluent [containing 1% bovine serum albumin in PBS
(300 µl)] for 1 h and washed with wash buffer. The samples
or standards (100 µl) were added to the well and incubated
for 2 h. The detection antibody (100 µl) was added to each
well and then incubated for 2 h at room temperature. A
working solution of streptavidin horseradish peroxidase (100
µl in ratio of 1:200) was added to each well and further
incubated for 20 min. The contents of the wells were exchanged
with substrate solution (100 µl) and incubated for 20 min.
Stop solution containing 2N H2SO4 (50 µl) was added and
the plate was gently tapped to ensure proper mixing. The
absorbance of each well was measured immediately at 450 nm
using a microplate reader. The results were expressed as pg/mg
protein.
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FIGURE 3 | The immunohistochemistry for tyrosine hydroxylase (TH) to detect the expression of the TH-immunoreactive (TH-ir) dopaminergic (DA)
neurons in the substantia nigra pars compacta (SNpc) and the TH-ir dopamine nerve fibers in the striatum. Values are expressed as percent mean ± SEM
(n = 3). The scale bar is 100 µm. (A) The number of TH-ir neurons was decreased in the SNpc of ROT-injected rats as compared to control (CONT) group. While,
BCP supplementation leads to increased expression of TH-ir neurons in ROT+BCP group as compared to ROT group. Furthermore, the ROT-BCP+AM630 group
showed decreased expression of TH-ir neurons as compared to ROT+BCP group. (B) Similarly, TH-ir DA nerve fibers immunofluorescence was also decreased in the
ROT group in comparison to the CONT group rats. Moreover, BCP supplementation increased the immunoreactivity of DA fibers as compared to ROT group. The
ROT-BCP+AM630 group showed TH-ir DA fibers expression similar to ROT group. (C,D) The number of TH-ir DA neurons in the SNpc was counted from each group.
A significant (*p < 0.05) decrease in the number of DA neurons was observed in the SNpc of the ROT group when compared to the CONT group. BCP treatment to
ROT administered rats significantly (#p < 0.05) protected the DA neurons from the ROT-induced neuronal death in the ROT+BCP group. The ROT-BCP+AM630
group also showed significantly (δp < 0.05) decreased number of DA neurons as compared to the ROT+BCP group. No significant differences were observed
between the DA neurons of the CONT and AM630-only group. (E) Immunofluorescence of the TH-ir DA fibers was observed in the striatum of different groups.
Significant (*p < 0.05) decrease in the TH-ir striatal DA fibers was observed in the ROT group as compared to the CONT group. Although, BCP supplementation of
ROT treated rats significantly (#p < 0.05) inhibited the loss of the TH-ir DA fibers in the ROT+BCP group as compared to the ROT group. ROT-BCP+AM630 group
showed significant (δp < 0.05) loss of the TH-ir DA fibers when compared to the ROT+BCP group. CONT and AM630-only group did not show any apparent loss of
TH-ir DA fibers.
Immunofluorescence Staining of TH
The brain from each rat was collected as described above
and sectioned for TH staining. Briefly, 14 µm coronal brain
sections were cut at the levels of the striatum and the SNpc
using a cryostat (Leica, Wetzlar, Germany). The sections were
washed twice with PBS (0.01 M, pH 7.4) and then incubated
with blocking reagent (10% normal goat serum in PBS, 0.3%
Triton-X 100) for 1 h. Further, the sections were incubated
with the primary polyclonal rabbit antibody against TH (1:500)
overnight at 4◦C. The sections were washed and incubated with
fluorescent secondary antibody Alexa Fluor R© 594 anti-rabbit
(1:1000) for 1 h at room temperature. The sections were then
washed and mounted using mounting medium Fluoroshield
TM
(Sigma Aldrich, MO, USA). Digital images of the sections were
captured using a fluorescence microscope (Olympus, Hamburg,
Germany).
Immunofluorescence Staining of GFAP and
Iba-1
Immunofluorescence staining of the striatum was performed
to examine the activation of GFAP positive astrocytes and
Iba-1 positive microglia. Brain sections were washed twice
with PBS and incubated with blocking reagent containing
10% normal goat serum and 0.3% Triton-X 100 in PBS for
1 h. The sections were then incubated with the primary
polyclonal rabbit antibody against GFAP (1:1000) and Iba-
1 (1:1000) overnight at 4◦C. The sections were washed
and incubated with fluorescent secondary antibody Alexa
Fluor R© 488 anti-rabbit for 1 h at room temperature. Sections
were then washed and mounted using mounting medium
FluoroshieldTM. Images were captured using a fluorescence
microscope, EVOS FL (Thermo Fisher Scientific, Waltham, MA,
USA).
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FIGURE 4 | The levels of malondialdehyde (MDA), glutathione (GSH), superoxide dismutase (SOD), catalase (CAT), and nitrite in the midbrain tissue.
Values are expressed as mean ± SEM (n = 6–8). ROT treatment caused significant (*p < 0.01) increase in MDA (A) and decrease in GSH level (B) in ROT challenged
rats as compared to vehicle injected control (CONT) rats. BCP treatment of ROT challenged rats showed significantly (#p < 0.05) decreased level of MDA and
increased (#p < 0.01) GSH level. However, CB2 antagonist AM630 administration prior to BCP treatment to ROT challenged rats significantly (
δp < 0.05) augmented
the level of MDA and GSH as compared to ROT+BCP group rats. The activity of the antioxidant enzymes: SOD (C) and CAT (D) was significantly (*p < 0.05)
decreased and nitrite (E) level was increased in the ROT group rats as compared to CONT group rats. BCP treatment of ROT administered ROT+BCP group rats
significantly (#p < 0.05) augmented the SOD and CAT activity and nitrite level in comparison to the ROT group. ROT-BCP+AM630 group rats showed significant
(δp < 0.05) decline in SOD and CAT activity and rise in nitrite level as compared to ROT+BCP group rats.
Assessment of Tyrosine
Hydroxylase-Immunoreactive (TH-ir)
Dopaminergic (DA) Neurons and TH-ir DA
Fibers
To determine the loss of the TH-ir neurons in the SNpc area,
three different levels of the SNpc region (−4.8,−5.04, and−5.28
mm of bregma) were counted and the average was presented as
a percentage. Loss of striatal fibers was evaluated by measuring
the optical density of TH-ir DA fibers in the striatum (adjacent to
0.3 mm of bregma) using Image J software (NIH, Bethesda, MD,
USA). For each rat, the optical density of TH-ir fibers within the
striatum was measured in three different, equally sized fields of
each section (three sections/rat). An average of the three areas
was calculated and presented as a percentage with reference to
the control. The optical density of the overlying cortex was taken
as a background measurement and subtracted from the value
generated from the striatum. The counting of TH-ir neurons
and measurement of optical density of the TH-ir fibers were
performed by an investigator blind to the experimental groups.
Assessment of Activated Astrocytes and
Microglia
A minimum of three coronal sections, from each animal,
at similar levels of the striatum were used to analyze the
number of activated astrocytes and microglia. Activation of
astrocytes and microglia was judged based on the intensity of
the immunofluorescence and the presences of extended glial
processes. Activated astrocytes and microglia were counted in
three, randomly chosen, different, equally sized fields, using
Image J software.
Western Blot Analysis of NF-κB, COX-2,
iNOS, and CB2
The striatal tissues from each experimental group were
homogenized in the buffer to prepare the cytoplasmic and
nuclear extracts as previously described by Arumugam et al.
(2011). The samples of the cytoplasmic and nuclear fractions
containing equal amounts of protein (35 µg) were separated
by gel electrophoresis using SDS-polyacrylamide (10%). The
proteins were transferred onto PVDF membrane and incubated
overnight at 4◦C with specific primary rabbit polyclonal
antibodies against NF-κB p65 (1:500), COX-2 (1:1000), iNOS
(1:500), and CB2 (1:500) followed by horseradish peroxidase-
conjugated secondary anti-rabbit antibody. The protein
recognized by the antibody was visualized using an enhanced
chemiluminescence pico kit (Thermo Fisher Scientific, Rockford,
IL, USA). The obtained blots were stripped and re-probed for
β-actin (1:5000; monoclonal mouse, Millipore, MA, USA) as
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a loading control. The intensity of bands was measured by
densitometry and quantified using Image J software.
Estimation of Protein Concentration
The protein contents in the sample were estimated using the
PierceTM BCA protein assay kit (Thermo Fisher Scientific,
Rockford, IL, USA) following the manufacturer’s instructions.
Statistical Analyses
The data were expressed as the mean value ± SEM. The data for
all parameters, unless otherwise stated, were analyzed using one-
way analysis of variance (ANOVA), followed by Tukey’s test to
calculate the statistical significance between various groups, using
software obtained from GraphPad InStat, La Jolla, CA, USA. In
all the tests, the criterion for statistical significance was set at
p< 0.05.
RESULTS
BCP Treatment Upregulates Expression of
CB2 Receptors
First, using western blot, we investigated, whether BCP
treatment is capable of selectively enhancing the expression
of CB2 receptors in the striatum region (Figures 2A,B). ROT
administration decreased the expression of CB2 receptors
as compared to CONT rats (62.56 vs. 100% control). BCP
administration prior to ROT increased the expression of
CB2 receptors in comparison to ROT-injected rats with no
pretreatment (89.67 vs. 62.56%). However, AM630, a selective
CB2 receptor antagonist, administered prior to BCP in ROT-
injected rats caused a noticeable decline in the expression of
CB2 receptors as compared to ROT+BCP group rats (70.22 vs.
89.67%). Further, we observed that AM630 administration to
ROT-injected rats did not cause any change in the expression
of CB2 receptors when compared to ROT-injected rats (63.28 vs.
62.56%). Additionally, the CONT andAM630-only groups of rats
also did not show any marked differences in the expression level
of CB2 receptors (98.19 vs. 100% control).
CB2 Receptor Activation Prevents Loss of
TH-ir DA Neurons in SNpc and TH-ir DA
Fibers in Striatum
To assess the neuroprotection afforded by BCP against the
neurodegeneration caused by ROT, we determined the TH-ir DA
neurons in the SNpc and optical density of TH-ir DA fibers in
the striatum (Figures 3A–E). ROT administration to rats caused
significant (p < 0.05) loss of DA neurons in the SNpc and
striatal DA fibers in comparison with vehicle-injected control
animals. However, BCP significantly (p < 0.05) prevented loss
of DA neurons induced by ROT in the SNpc and striatal DA
fibers compared to the ROT group of animals. Interestingly, this
protective effect of BCP was significantly (p < 0.05) reversed
by the prior administration of CB2 antagonist AM630 to rats
administered with ROT and BCP. These results are indicative
of the CB2 receptor-mediated neuroprotective effects of BCP.
In contrast, AM630 administration alone did not show any
deleterious effects on the DA neurons and striatal fibers.
CB2 Receptor Activation Attenuates the
Level of MDA and GSH in the Midbrain
ROT administration significantly (p < 0.01) increased MDA
content (Figure 4A) and decreased (p < 0.01) the level of GSH
(Figure 4B) as compared to control group animals. However,
BCP pretreatment of ROT-administered rats caused a significant
(p < 0.05) reduction in MDA level and prevented (p < 0.01)
decline of GSH level. In contrast, in ROT-challenged rats,
administration of AM630 before BCP significantly (p < 0.05)
diminished the effect of BCP on MDA reduction and GSH
restoration (Figures 4A,B). Interestingly, the AM630-only group
did not show alteration in the level of either MDA or GSH as
compared to control animals.
CB2 Receptors Activation Augments
Antioxidant Enzymes Activity in the
Midbrain
The activities of antioxidant enzymes: SOD (Figure 4C) and
CAT (Figure 4D) was significantly (p< 0.05) decreased in ROT-
injected rats compared to control rats. However, a significant
(p < 0.05) increase in the activity of SOD and CAT was
observed in BCP-treated rats as compared to ROT-injected rats.
In contrast, AM630 administration diminished the effects of BCP
in ROT-challenged rats (Figures 4C,D). The antioxidant enzyme
activity of SOD and CATwas unaltered in the AM630-only group
of animals.
CB2 Receptors Activation Inhibits
Increased Nitrite Level in the Midbrain
The nitrite levels were significantly (p < 0.05) increased in the
ROT-administered rats as compared to control rats (Figure 4E).
However, treatment with BCP produced a significant (p <
0.05) decrease in the level of nitrite and that in turn was
significantly (p < 0.05) attenuated by the CB2 receptor
antagonist, AM630 (Figure 4E). In contrast, administration
of CB2 receptor antagonist AM630-only did not cause any
significant change in the nitrite level.
CB2 Receptor Activation Alleviates
ROT-Induced Glial Cell Activation in the
Striatum
Immunofluorescence staining of GFAP and Iba-1 was carried
out to determine the morphological changes in astrocytes
and microglia, respectively. In the ROT-administered rats, a
noticeable rise in immunofluorescence of GFAP and Iba-1 was
observed, which is indicative of the activation of astrocytes
and microglia, the features observed in PD neurodegeneration.
However, BCP treatment showed a comparatively decreased
immunofluorescence of GFAP and Iba-1 (Figures 5A,B).
Additionally, a quantitative evaluation for GFAP-positive
astrocytes and Iba-1-positive microglia was performed in the rats
of different experimental groups (Figures 5C,D). ROT-injected
rats showed a significantly (p< 0.05) higher number of activated
astrocytes and microglia compared to control animals, whereas
BCP pretreatment of ROT-injected rats created a significant
(p < 0.05) reduction in the number of activated astrocytes
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FIGURE 5 | The immunofluorescence staining to detect the expression of glial fibrillary acidic protein (GFAP) positive astrocyte and ionized calcium
binding adaptor molecule-1 (Iba-1) positive microglia in the striatum. Values are expressed as percent mean ± SEM (n = 3). The scale bar is 200 µm.
Profound expression of GFAP positive astrocytes (A) and Iba-1 positive microglia (B) was found in the ROT-administered and ROT-BCP+AM630 groups as compared
to the vehicle-injected CONT and AM630-only groups. While BCP supplementation to ROT-injected rats showed moderate staining of GFAP and Iba-1 as compared
to ROT-injected rats. Quantitative analysis of activated astrocytes (C) and microglia (D) has shown that significant (*p < 0.05) increase in number of activated
astrocytes and microglia was observed in the ROT group as compared to the CONT group. However, BCP supplementation significantly (#p < 0.05) reduced the
number of activated astrocytes and microglia in the ROT+BCP group as compared to the ROT group. The ROT-BCP+AM630 group also showed significantly (δp <
0.05) increased number of activated astrocytes and microglia when compared to the ROT+BCP group. The CONT and AM630-only groups did not show any marked
difference in the activation of astrocytes and microglia.
and microglia as compared to ROT-challenged rats. Further,
AM630 administration prior to BCP supplementation to ROT
injected animals showed increase in the number of activated
astrocytes and microglia clearly demonstrating the CB2 receptor-
mediated activity of BCP. However, AM630 alone did not have a
significant effect on the activation or number of astrocytes and
microglia.
CB2 Receptors Improve the Level of
Proinflammatory Cytokines in the Midbrain
ROT administration created a significant (p < 0.05) increase
in the level of proinflammatory cytokines such as IL-1β
(Figure 6A), IL-6 (Figure 6B), and TNF-α (Figure 6C)
as compared to the control group while treatment with
BCP significantly (p < 0.05) attenuated the rise of
these proinflammatory cytokines in ROT-injected rats
(Figures 6A–C). However, AM630 administration before
BCP abrogated the protective effects of BCP against ROT-
induced elevated levels of proinflammatory cytokines. The CB2
receptor antagonist AM630 alone, did not have any effect on the
level of proinflammatory cytokines.
CB2 Receptor Activation Attenuates
Inflammatory Mediators NF-κB, COX-2 and
iNOS
To detect and quantify the activation of NF-κB, the translocation
of NF-κB p65 subunit to the nucleus was assayed in the
striatal nuclear extracts using a subunit specific anti-NF-κB
p65 antibody. As depicted in Figures 7A,C, the rats injected
with ROT showed a remarkably higher level of NF-κB p65 as
compared to the controls (171.7 vs. 100% control). However,
treatment with BCP to ROT-administered rats produced a
decrease in NF-κB p65 levels as compared to the ROT group
(112.38 vs. 171.7%). In contrast, the CB2 receptor antagonist
AM630 administered prior to BCP in ROT-injected rats
increased the level of NF-κB p65 expression as compared to the
ROT+BCP group (171.55 vs. 112.38%).
We further investigated the protein expression level of NF-κB
responsive genes such as COX-2 and iNOS in the cytoplasmic
fraction of the striatal tissue (Figure 7B). Similar to NF-κB p65,
the expression level of COX-2 and iNOS increased in ROT-
challenged rats as compared to control rats (COX-2: 213.48 vs.
100% control; iNOS: 251.56 vs. 100% control). However, BCP
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FIGURE 6 | The pro-inflammatory cytokines: IL-1β, IL-6, and TNF-α were measured by enzyme linked immunosorbent assay (ELISA) in the midbrain.
Values are expressed as mean ± SEM (n = 6–8). The level of IL-1β (A), IL-6 (B), and TNF-α (C) was significantly (*p < 0.05) increased in the ROT group when
compared to the CONT group. Although, BCP supplementation significantly (#p < 0.05) decreased the ROT-induced increase of these proinflammatory cytokines in
the ROT+BCP group. The ROT-BCP+AM630 group showed significantly (δp < 0.05) increased level of IL-1β, IL-6, and TNF-α as compared to the ROT+BCP group.
There is no significant difference in these cytokines between the CONT and the AM630-only group.
pretreatment of ROT-challenged rats decreased the elevated level
of COX-2 and iNOS as compared to ROT injected animals
(COX-2: 143.6 vs. 213.48%; iNOS: 158.12 vs. 251.56%). However,
AM630 administration before BCP has abrogated the beneficial
effect of BCP against COX-2 and iNOS in animals treated with
ROT (COX-2: 205.6 vs. 143.6%; iNOS: 247.18 vs. 158.12%)
(Figures 7D,E). Similar to oxidative stress and morphological
parameters, no significant changes in the levels of NF-κB, COX-
2 and iNOS were observed in the AM630-alone group of
rats.
DISCUSSION
The current therapies for PD are still inadequate. Therefore,
intensive efforts are made to identify promising new targets for
the treatment of PD. Until now, the exact cause of PD has yet to
be established even though environmental factors, in addition to
genetic factors, have been demonstrated to play a significant role
in the causation of PD. Based on the environmental factors, the
present study employed the ROT-induced rat model of PD that
is widely used for the evaluation of novel pharmacotherapeutic
agents and understanding of etiopathogensis. ROT has been
shown to cause PD with the inhibition of mitochondrial
complex I of the respiratory chain and activation of abnormal
dopamine metabolism (Betarbet et al., 2000; Sherer et al.,
2007), along with oxidative stress and inflammation, which
causes neurodegeneration of DA neurons in the SNpc region
of the PD brain (Johnson and Johnson, 2015). The results
from the present study showed that ROT causes loss of
dopaminergic neurons in the SNpc and the striatal dopaminergic
nerve terminals. This correlates with the degeneration of
the nigrostriatal pathway, which plays an important role in
the co-ordination of motor functions. The degeneration of
nigrostriatal pathways has been shown to be associated with the
occurrence of oxidative/nitrosative stress, which subsequently
leads to the induction of neuroinflammation and subsequent
neurodegeneration (Hald and Lotharius, 2005; Cannon et al.,
2009; Lee et al., 2009). In recent years, the cannabinoid receptors,
specifically activating CB2 receptors, appear to represent a novel
therapeutic target for neurodegenerative diseases, including PD,
because of their role in counteracting oxidative stress and
inflammation. The CB2 receptors have recently emerged as a
potential anti-inflammatory target, to break the self-sustaining
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FIGURE 7 | Western blot analysis of NF-κB p65, COX-2, and iNOS in the striatal tissue. Values are expressed as percent (%) mean ± SEM (n = 3). Expression
level of NF-κB p65 (A) COX-2 and iNOS (B) was carried out by western blot. (C) ROT-administered group rats showed increase in nuclear NF-κB p65 level as
compared to control group (171.7 vs. 100% control). BCP treatment of the ROT-challenged rats decreased the NF-κB p65 expression when compared to the ROT
group (112.38 vs. 171.7%). The ROT-BCP+AM630 group had shown increased expression of NF-κB p65 as compared to the ROT+BCP group (171.55 vs.
112.38%). (D) ROT-injected rats showed increased COX-2 level as compared to the CONT rats (213.48 vs. 100% control). BCP supplementation to ROT-injected rats
showed decreased expression of COX-2 as compared to ROT group rats (143.6 vs. 213.48%). ROT-BCP+AM630 group rats showed increase in COX-2 expression
as compared to the ROT+BCP group rats (205.6 vs. 143.6%). (E) Likewise, iNOS expression was increased in the ROT group rats as compared to the CONT group
rats (251.56 vs. 100% control). BCP treatment decreased iNOS expression as compared to the ROT group rats (158.12 vs. 251.56%). The ROT-BCP+AM630 group
showed increase in iNOS expression when compared to the ROT+BCP group (247.18 vs. 158.12%).
cycle of neuroinflammation and preserve neuronal homeostasis,
and survival in neurodegenerative disorders (Ramírez et al.,
2005; Palazuelos et al., 2008; Price et al., 2009; Sagredo et al.,
2009; Gómez-Gálvez et al., 2016). The activity of CB2 receptors
is implicated in the reduction of proinflammatory mediators
in response to noxious stimuli and in control of neuronal
survival (Fernandez-Ruiz et al., 2007). Recently, changes in
CB2 receptors have been shown in the mice model of PD
induced by intrastriatal lesions with lipopolysaccharides (García
et al., 2011). Genetic studies have also shown that CB2 receptor
knockout-mice display microglial activation, neural pathology,
and functional deficits in the MPTP-induced mice model of
PD (Price et al., 2009). The CB2 receptor expression has been
demonstrated in the central nervous system, including the SNpc
area of PD brains (García et al., 2015). A recent report also
suggests that CB2 receptors modulate the dopamine dependent
neuronal activity and behavior in mice (Zhang et al., 2014).
Because of potent anti-inflammatory and antioxidant action,
and no psychoactive adverse reactions caused by CB2 receptor
activation, the therapeutic targeting of CB2 receptor appears to
be promising for modulation of neuroinflammation and disease
modification in PD.
In addition, ROT has been reported to inhibit complex I of
the mitochondrial respiratory chain, which consequently leads
to the formation of ROS, such as superoxide, hydroxyl radical
and peroxynitrite. The induction of ROS is critical in the SNpc
because of low levels of antioxidant defenses corresponding to a
very high level of dopamine metabolism in this region (Thakur
and Nehru, 2013). To determine antioxidant tissue defense,
we assessed the oxidative/nitrosative stress parameters such as
activities of antioxidant enzymes like SOD and CAT; and the
levels of GSH, total nitrite, and MDA, in the midbrain tissues.
The occurrence of lipid peroxidation is a key pathogenic event
in tissues, resulting from an imbalance between ROS generation
and the availability of endogenous cellular antioxidant defense.
We observed that the ROT-challenge caused a significant rise
in the MDA level, with a concomitant decline in the GSH level
in the midbrain tissues. Interestingly, treatment with BCP of
ROT-injected rats inhibited lipid peroxidation evidenced by the
reduced MDA levels followed by restoration of the GSH content.
The decline in the MDA content and concomitant restoration
of GSH content by BCP can be ascribed to the potent chain
breaking, free radical scavenging, and antioxidant activity of BCP
(Chang et al., 2007).
Apart from non-enzymatic antioxidants, the cells are also
equipped with the enzymatic defense system, which includes
SOD and CAT, as an important component in neutralizing
the ROS load. The present study showed that ROT caused
a significant reduction in the activities of SOD and CAT
enzymes as compared to control rats. However, BCP treatment
of ROT-challenged rats showed a significant restoration of SOD
and CAT activities. Furthermore, in ROT-challenged rats, we
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FIGURE 8 | Schematic representation of the neuroprotective mechanism of action of BCP.
observed a significant rise in the total nitrite levels, due to
the production of nitric oxide that generates peroxynitrite on
reaction with superoxide anion leading to robust neurotoxicity
(Beckman et al., 1990). BCP treatment of ROT-challenged rats
significantly counteracted any rise in nitrite levels. The reversal
of these beneficial effects of BCP against oxidative stress by prior
administration of AM630, a selective CB2 receptor antagonist,
clearly demonstrates CB2 receptor-dependent activity of BCP.
To our knowledge, the present study is the first to report that
BCP reduces oxidative stress in ROT-induced dopaminergic
neurodegeneration by activating CB2 receptors.
Previous studies have demonstrated gliosis with increased
expression of GFAP and Iba-1 in human PD brains that appears
to be age dependent and related to the disease progression
(Yan et al., 2014). The glial cells mediating neuroinflammation
have recently emerged as key players in the pathogenesis of
PD; and the activation of microglia in the nigrostriatal regions
of the PD brains is believed to be a rapid cellular response
to inflammation (Hirsch et al., 2003; Gordon et al., 2012). In
our study, the hypertrophy with long processes, along with the
increased immunofluorescence of GFAP and Iba-1, represents
activated astrocytes and microglia, respectively. However, BCP
treatment reduced the activation of astrocytes and microglia,
which supports its anti-inflammatory action in-line with the
reported activity of several other agonists of the CB2 receptors
(Marchalant et al., 2008). Furthermore, it was expected that a
CB2 receptor antagonist should reverse or abolish the protective
effects of BCP, as indeed was the case, as the administration
of AM630, abrogated the effects of BCP regarding glial cell
activation. The findings clearly demonstrate a functional CB2
receptor dependent mechanism in the protective effects of BCP.
Moreover, microglia activation leads to the nuclear
translocation of transcription factor NF-κB, which upregulates
the release of inflammatory mediators such as COX-2 and
iNOS as well as induction of proinflammatory cytokines such
as IL-1β, IL-6, and TNF-α in PD (Mosley et al., 2006). The
transcription factor NF-κB also plays an important role in the
regulation of several proinflammatory mediators that are directly
involved in the initiation of neuroinflammation and subsequent
neurodegeneration. The inactive form of NF-κB is present in
the cytoplasm in association with the inhibitory protein IκB,
which prevents its nuclear translocation that is required for
transcriptional activity. The IκB phosphorylation followed by
proteolytic degradation results in the translocation of a free p65
subunit of NF-κB to the nucleus where it binds to target DNA
elements (gene promoters containing κB binding sites) and
regulates transcription of several proinflammatory genes such as
iNOS, COX-2, IL-1β, IL-6, and TNF-α (Shen et al., 2010). These
inflammatory enzymes (COX-2 and iNOS and proinflammatory
cytokines IL-1β, IL-6 and TNF-α) are known to be cytotoxic to
neurons and to lead to neuronal cell death (Hald and Lotharius,
2005). Numerous studies have reported that cannabinoid
ligands inhibit the production of proinflammatory cytokines
such as TNF-α, IL-1β, and IL-6; and suppress production of
proinflammatory mediators by microglia and macrophages, by
CB2 receptor modulation (Correa et al., 2005; Klein, 2005; Zhao
et al., 2010).
Our study demonstrates that BCP inhibited the ROT-induced
nuclear translocation of NF-κB p65, whereas administration of
AM630 prior to BCP supplementation to ROT-injected rats
diminished the beneficial effects of BCP. We also observed
elevated expression of inflammatory mediators COX-2 and iNOS
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in ROT-challenged rats. BCP treatment of ROT-challenged rats
modestly decreased the expression of COX-2 and iNOS, which
supports its anti-inflammatory activity as reported by others
(Cho et al., 2007; Bento et al., 2011). In contrast, the anti-
inflammatory effect of BCP against increased expression of COX-
2 and iNOS was abolished by prior administration of AM630.
Additionally, proinflammatory cytokines (IL-1β, IL-6, and TNF-
α) were also found significantly increased after ROT-challenge of
the rats. BCP treatment significantly decreased the elevated levels
of these proinflammatory cytokines in ROT-injected rats. In
contrast, AM630 antagonized the protective effect of BCP against
the proinflammatory cytokines. Taken together, these results
demonstrate that the beneficial effects of BCP were reversed
by AM630. To conclude, the abrogation of the BCP effects
by AM630 clearly demonstrates that the activity of the central
cannabinoid receptors plays an important role in mediating of
the neuroprotective action of BCP in ROT-induced PD.
Further, the observed neuroprotective activity of BCP in
the present study was also supported by a previous in vitro
study, where BCP (among a group of triterpenoids screened
for pharmacological activity) showed the highest neuroprotective
effects due to favorable physicochemical properties, including
high lipophilicity (Chang et al., 2007). The lipophilicity of BCP
and AM630 are both more than four, which is strongly indicative
of their ability to permeate the blood brain barrier and of their
bioavailability in the brain. The CB2 receptor antagonist AM630
is a protean ligand and inverse agonist that targets a constitutively
active form of CB2 receptor in the brain (Bolognini et al., 2012).
The CB2 receptor ligands are generally classified as agonists,
antagonists and inverse agonists showing positive, neutral and
negative efficacy, respectively, for a particular signaling pathway.
They show varying potency and efficacy termed as “functional
selectivity” or “biased agonism” (Pertwee et al., 2010), and pave
the way to the design of agents, which may activate the specific
pathways required for therapeutic benefit. The abrogation of
CB2 receptor mediated effects by AM630 demonstrates the CB2
receptor dependent mechanism and has been shown in a number
of studies (Hosohata et al., 1997).
The data in our study is in agreement with previous studies of
the action of BCP and AM630 at CNS level (Choi et al., 2013).
The previous report of the effects of BCP in enhancing cognition,
preventing dependence and alleviating anxiety, depression, and
compulsion is further supported by our current findings (Al
Mansouri et al., 2014). Taken together, the abrogation of the
protective effects of BCP by AM630 demonstrates the CB2
receptor-dependent mechanism of BCP and the findings can be
extrapolated to the neuroprotective properties of CB2 agonism in
PD.
CONCLUSION
In conclusion, the present study demonstrates that the plant-
derived, sesquiterpene compound, BCP, exhibits potent anti-
inflammatory and antioxidant effects in the ROT-induced
rat model of PD. The major underlying mechanism is the
activation of CB2 receptors, which results in attenuation of
oxidative/nitrosative stress and neuroinflammation, inhibition
of gliosis and pro-inflammatory cytokine release, and decline
in the nigrostriatal degeneration. A diagram of the proposed
underlying mechanism has been shown in Figure 8. Our findings
clearly demonstrate that CB2 receptors may be an attractive
therapeutic target for PD and BCP could be an attractive
candidate molecule for the treatment of PD. Furthermore,
BCP may be the first CB2 receptor agonist and plant derived
cannabinoid to be developed in the quest for novel compounds
that might improve conventional therapies as well as provide
novel disease-modifying agents.
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